GEMoaB Monoclonals GmbH is working with several companies and partners interested in the joint development of novel therapeutics based on our platform technology. We are open for new strategic collaborations and also ready to generate a bi-specific antibody based on your target binding moiety of choice. Please contact us for further details.

Fraunhofer Institute for Toxicology and Experimental Medicine
Cellex Gesellschaft für Zellgewinnung GmbH
CMT Cellex Medical Transports
CMS Cellex Medical Services
CPT Cellex Patient Treatment GmbH
Celgene Corporation
GCP Service Bremen


Supported by

SAB Sächsische Aufbaubank-Förderbank

European Union/ European Social Fund

Federal Ministry of  Education and Research